Cutaneous leishmaniasis
ICD-10 B55.1 · ICD-11 1F54.1

Treatment of Cutaneous Leishmaniasis Caused by Leishmania guyanensis

Cutaneous leishmaniasis caused by Leishmania guyanensis requires a species-specific management approach. Local treatment is not recommended for this species due to insufficient data, making systemic therapy the appropriate path forward.

Clinical Scenario

Cutaneous leishmaniasis caused by Leishmania guyanensis. No recommendation for local treatment is possible due to lack of data; systemic management is required for this species.

Treatment Approach & Goals

Systemic treatment is indicated. The protocol identifies specific antiprotozoal agents as options for this species. The clinical goal is complete reepithelialization — full healing of the cutaneous lesion.

Full agent selection, dosing, sequencing, and monitoring parameters are available in the complete protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/jtm.12089

  • Treatment of L. guyanensis
  • 1. Pentamidine isethionate (4 mg/kg: three infusions over 5 days) [A].
  • 2. Miltefosine (50 mg tid × 28 days) [B]
  • Pentamidine is the first line treatment for L. guyanensis CL in French Guyana, Surinam, and Brazil, with cure rates around 90%.
  • Treatment failure is present when reepithelialization is incomplete 3 months after starting therapy.
View source ↗